X

Trial Profile

A Phase 1 Study of DS-1001b in Patients with IDH1 Mutated Gliomas

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 01 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Safusidenib (Primary)
Indications Glioma
Focus Adverse reactions; First in man

Most Recent Events

10 Apr 2024 According to a Nuvation Bio media release, AnHeart Therapeutics has been acquired by Nuvation Bio and AnHeart is now a wholly-owned subsidiary of Nuvation Bio.
14 Feb 2023 Results assessing the safety, pharmacokinetics, pharmacodynamics, and efficacy of DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas published in the Neuro-Oncology
12 Mar 2021 Planned End Date changed from 1 Mar 2022 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com